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Abstract:  Bacillus anthracis, the agent of anthrax, has gained virulence through its 
exotoxins produced by vegetative bacilli and is composed of three components forming 
lethal toxin (LT) and edema toxin (ET). So far, little is known about the effects of these 
toxins on the eukaryotic cytoskeleton. Here, we provide an overview on the general effects 
of toxin upon the cytoskeleton architecture. Thus, we shall discuss how anthrax toxins 
interact with their receptors and may disrupt the interface between extracellular matrix and 
the cytoskeleton. We then analyze what toxin molecular effects on cytoskeleton have been 
described, before discussing how the cytoskeleton may help the pathogen to corrupt general 
cell processes such as phagocytosis or vascular integrity. 
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1. Introduction 
Bacillus anthracis, the agent of anthrax, is a common veterinary disease and major agent of 
biological warfare important for biodefense [1]. The attacks in 2001, consisting of letters contaminated 
with anthrax spores in the United States, have confirmed its potential use as a weapon of bioterrorism 
and justify the growing need to understand the pathophysiology of this dreadful pathogen [2].   
B. anthracis is a gram-positive, aerobic bacterium that can form very resistant spores in poor 
environments. Its virulence is linked to two main factors: the capsule formed by poly γ-D-glutamic 
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acid, whose operon is encoded by the plasmid pXO2, and the two toxins (edema toxin (ET) and lethal 
toxin (LT)) encoded on the other virulence plasmid named pXO1 [3,4]. By pulmonary route of infection, 
B. anthracis induces a toxemia associated with sepsis and respiratory distress within a few days, 
rapidly progressing to death without treatment [5,6]. Anthrax toxins play a central role in pathogenesis 
and deregulation of the immune system (review in [7,8]). At the cellular level, many toxin effects have 
been described (review in [4,9]). Some studies have suggested that the toxins also target the 
cytoskeleton [10–15]. We attempt here to review how the anthrax toxins may interact with the 
cytoskeleton, a crucial component of eukaryote cells crucially involved in homeostasis. 
2. General Overview on Bacillus anthracis Toxins and the Cytoskeleton 
2.1. Bacillus anthracis Toxins  
The toxins are A/B type, formed by the association of three components. Components A bear the 
enzymatic activity. Edema factor (EF, 89 kDa) for ET is a calmodulin-dependent adenylate cyclase, 
that increases intracellular cAMP concentrations [4,16], while lethal factor (LF, 90 kDa) for LT is a 
zinc-dependent metalloprotease cleaving specifically the N-terminus of most mitogen-activated protein 
kinase kinases (MAPKK or MEK) [4,17]. This MEK cleavage disrupts signaling cascades essential in 
cell proliferation, cell cycle regulation and immune function, such as ERK 1/2, JNK/SAPK and p38, 
signaling pathways (review in [4,7]). The B component, involved in binding cell receptor, is common 
for both toxins: it is named protective antigen (PA, 83 kDa), after its immunogenic properties (review 
in [9,18]). The mechanisms of cell penetration by toxins have been thoroughly deciphered over the 
past twenty years and can be separated into three major steps: receptor binding, internalization, 
membrane translocation (reviewed in [9,18]). PA83 binding to specific cell receptors (ANTXR1 or 
TEM-8 for Tumor Endothelial Marker-8 and ANTXR2 or CMG-2 for Capillary Morphogenesis 
Protein-2) [19] allows its cleavage by a furin-like protein into two subunits of 63 and 20 kDa, the latter 
being released (Figure 1). A third co-receptor named LDL receptor protein (LRP)-6 has been   
proposed [20], while its effective role has been discussed and may be cell-type specific [21,22]. 
Interestingly, a group has demonstrated that anthrax toxin receptors interact with LRP6 to control Wnt 
signaling [23].  
PA63 subunits associate in heptamers to form a pre-pore, redistributed to the cell surface in lipid 
rafts. This allows the binding of EF or LF components in a stoichiometric ratio of 3 LF/EF to 7 PA. 
The toxin-receptor complex is then internalized by clathrin-dependent endocytosis [9,24,25]. A pH 
decrease within early endosomes results in the translocation of these factors in multivesicular bodies 
(MVB), finally merging with the intracellular membrane of late endosomes. This last step facilitates 
the translocation of LF into the cytoplasm, while EF stays associated to the membrane of the late 
endosome [26]. Its perinuclear localization generates intracellular cAMP gradients from the cell 
nucleus to the periphery. Interestingly, mouse mutants for each toxin receptor have been produced, 
showing that CMG-2 plays a unique role as a major receptor of anthrax toxin in vivo [27].  
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Figure 1. Interactions between anthrax toxin receptors and cytoskeleton.  This figure 
highlights the links between cytoskeleton, anthrax toxin receptor (ANTXR) and the 
extracellular matrix. The physiological roles of ANTXR are not well known so far, unless 
they interact with extracellular matrix fibers. Their intracellular tail interacts with actin, 
and there is an inverse correlation between the binding of TEM8 to actin and the amount of 
protective antigen (PA) bound to receptors. After PA-ANTXR interaction, at least several 
signals can be sent to trigger PA endocytosis: (i) PA-ANTXR interactions trigger src-like 
kinase which in turn phosphorylates CMG-2 and TEM-8 intracellular tail favoring the 
toxin intracellular entry; (ii) a second target for anthrax receptor signaling may be ARAP3 
(Arf GAP and Rho GAP with ankyrin repeat and pleckstrin homology domains); (iii) LRP6 
coreceptor control Wnt signaling.  
 
2.2. The Cytoskeleton  
The cytoskeleton is a cellular scaffolding system whose functions include broad fundamental cell 
processes such as morphology and plasticity maintenance, movement, signal transduction, membrane 
and organelle trafficking. The cytoskeleton consists of three filament systems integrated into a 
complex network regulated by associated proteins: (i) actin microfilaments; (ii) microtubules; and 
(iii) intermediate filaments. As anthrax toxin effects have been described only on actin filaments and 
microtubules, we will restrict our description on these two systems. 
Microfilaments are formed by a globular protein called actin, which exists in unpolymerized   
(G-actin) and polymerized (F-actin) forms. F-actin is composed of two parallels strands of actin 
monomers. The dynamic and spatial organization of the actin cytoskeleton is regulated at multiple 
levels by a variety of proteins that control numerous processes such as nucleation, polymerization, 
stabilization, branching and cross-linking of actin filaments [28–30]. Moreover, these regulatory and 
structural proteins enable cells to form and remodel functional structures like stress fibers, 
lamellipodia, filopodia, phagosomes and endocytic vesicles [30–32]. These macromolecular scaffolding 
structures are regulated by a complex interplay of Rho GTPases, kinases and phosphatases, which are 
again affected by bacterial pathogens or toxins [33,34]. The Rho GTPases are master regulators of Toxins 2012, 4                 
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cytoskeletal dynamics and cell shape [35], immune responses [36,37] and phagocytosis [38]. The three 
best-known members of the Rho GTPases family include RhoA, Cdc42 (Cell division Cycle 42) and 
Rac1, all of which can act as actin regulator switches by cycling between an inactive GDP- and active 
GTP-bound states [28,34]. In their active GTP-bound state, Rho GTPases interact with downstream 
effectors involved in the dynamic rearrangement of actin and microtubule filaments. Activation of 
RhoA induces the formation of stress fibers that are contractile bundles of polymerized actin containing 
myosin motor proteins. Rac1 regulates the formation of membrane ruffles or lamellipodia and Cdc42 
controls the formation of filopodia or finger-like cell protrusions at the cell periphery [31,34,35]. 
Microtubules form well-organized hollow tubes composed of covalent association of alpha/beta 
tubulin heterodimers. These protofilaments radiate from the microtubule-organizing center (MTOC) 
located at the centrosome in the cytoplasm, in order to allow directional flow of proteins and 
organelles to a specific location [39,40]. The complex organization of microtubules is responsible for 
cell polarity, leading to MTOC’s movement toward the site of phagocytosis [41]. The Rho GTPases 
and many microtubule-associated proteins (MAPs), motor proteins like dyneins, and kinesins also 
interact with microtubules [37,40]. 
As the cytoskeleton intervenes in many dynamic cell processes, it has to be controlled by many 
regulatory proteins and is the target of multiple signaling pathways. As a result, the cytoskeleton 
network is a prime target for pathogens and their virulence factors.  
3. Association between Anthrax Receptor, Extra-Cellular Matrix and the Cytoskeleton  
It is interesting to note that the precise physiologic role of TEM-8 and CMG-2 is currently 
unknown, although mutations of TEM-8 and CMG-2 in humans strongly suggest their role is very 
different from toxin endocytosis (review in [42]). Mutation in the cmg-2 gene is linked to juvenile 
hyaline fibromatosis (JHF) and infantile systemic hyalinosis (ISH) [43,44]. Clinically, the patients 
suffer from generalized fibromatosis resulting by deposition of hyaline in the dermis. Mutation in the 
extracellular domain of tem-8 has been described in a patient with infantile hemangioma, characterized 
by a rapidly growing area of angiogenesis [45]. Intriguingly, TEM-8 mutation disrupted the expression 
of VEGFR1 and VEGFR2 signaling. Taken together these data strongly suggests that TEM-8 and 
CMG-2 have very specialized functions hijacked by anthrax toxins. Along those lines the anthrax toxin 
triggers src-like kinase which in turn phosphorylates CMG-2 and TEM-8 intracellular domain favoring 
toxin entry [46]. A second target for anthrax receptor signaling may be ARAP3 (Arf GAP and Rho 
GAP with ankyrin repeat and pleckstrin homology domains) [47].  
Extracellular domain of CMG-2 is known to interact with collagen IV and laminin [48]. 
Extracellular domain of TEM-8 interacts with collagen I and VI, and gelatin [15,49,50]. The cytosolic 
tail of TEM8 directly docks the actin cytoskeleton, helping cell spread by coupling matrix ligand to 
intracellular cytoskeleton [15]. TEM-8 seems to organize actin filaments into bundles [51], suggesting 
that potential actin reorganization drives cell shape changes and spreading after PA attachment.   
In addition, TEM8-1, but not TEM8-2 interacts with the actin network which modulates affinity for PA 
and promotes its heptamerization [25,51,52]. An inverse correlation exists between TEM8 binding to 
actin and the amount of PA bound to receptors [51]. Cortical actin cytoskeleton seems to be required 
for heptamerization of PA when bound to TEM8-1 that is organized in an actin dependent manner, but Toxins 2012, 4                 
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not when bound to CMG2. Upon toxin binding, actin-TEM8 interaction is released, but actin remains 
essential for heptamerization and endocytosis of heptameric PA [25]. However, future studies are 
required to better understand the role of the cytoskeleton in toxin uptake and intoxication. 
4. Anthrax Toxins and Disruption of the Cytoskeleton Network  
4.1. LT Effects  
The effects of LT on the cytoskeleton have been relatively recent discoveries. Most of the studies 
have focused upon actin in endothelial and epithelial cells, as well as immune cells like macrophage or 
neutrophils (Figure 2). 
Figure 2. Effects of anthrax lethal and edema factors on cytoskeleton regulatory pathways. 
This hypothetical figure describes anthrax lethal factor (LF, red) and edema factor   
(EF, green) main targets along the regulatory pathways of cytoskeleton. On the one   
hand, LF probably activates Cdc42 and/or ROCK. ROCK activation could increase   
Myosin Light Chain (MLC) phosphorylation, leading to cell contractility. In parallel,   
LF-Mitogen-Activated Protein Kinase (MEK) cleavage blocks the Hsp27 phosphorylation 
cycle, impairing actin monomer transport to an area of new actin filament assembly. On 
the other hand, EF increases the cAMP level which signals via PKA and/or Epac/Rap1, 
potentially leading to the activation of Rac1 and inducing protrusions and retraction of the 
membrane. In parallel, EF could inhibit RhoA, leading to a reduction of F-actin via   
cofilin activation. 
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4.1.1. Actin Network 
One major issue when considering the effects of LT on various cells is its diverse effects. On one 
hand, after exposure to LT, human endothelium and lung epithelial cells progressively show mechanical 
stiffness [11], blebbing, and elongation [53,54]. These morphological changes correlate with   
re-organization of the actin cytoskeleton characterized by thick actin cables or actin stress fibers [53–56] 
parallel to each other, with loss of cortical F-actin [53,54] but increased central F-actin content [11,54] 
or increased actin filament assembly [11]. For many authors, unconventional formation and 
stabilization of stress fibers occurred in the presence of LT over a course of 6–24 h, i.e. (i) in the 
absence of direct activation of RhoA/ROCK pathway or Rac1 by LT [11,53]; (ii) with equivalent 
phosphorylation of both cofilin [11,53] and myosin light chain (MLC) [53]; (iii) requires host gene 
transcription modifications by LT to participate in the thick actin cable formation [11,53]. For Cdc42 
activity, results are more divergent: Lehmann et al. observe an increase in active GTP-bound Cdc42 in 
LT-treated epithelial cells [11] while Rolando et al. show equivalent activity of Cdc42 in   
LT-intoxicated human endothelial cells [53]. 
In contrast to the previous studies, a recent study of Warfel et al. on lung microvascular endothelial 
cells shows actin stress fibers accompanied by increased MLC phosphorylation and cleavage of 
ROCK-1, leading to the activation of ROCK-1 after 72 h of LT exposure. ROCK-inhibitors seem to 
block LT-induced stress fiber formation and phosphorylation of MLC, suggesting an involvement of 
ROCK pathways in maintaining LT-induced stress fibers [56]. Consequently, RhoA/ROCK pathway is 
most likely not directly modulated by LT but may control the stability of these actin cables. 
On the other hand, after 2 h, LT reduces the ability of neutrophils to spread and actin filament 
assembly at the leading edge [13,57]. Actin-based motility of the intracellular pathogen Listeria 
monocytogenes in HeLa cells is also affected by LT [14]. In proteomics studies on mouse macrophage, 
the beta isoform of actin is upregulated [58], but gamma actin is decreased [59]. The study by   
Nour et al. also describes LT-treated murine macrophages lacking actin cytoskeleton after 90 min [60]. 
All these studies may also implicate one or all of the three major MAPK pathways altered in  
LT intoxication [61]. The effect of LT on neutrophil actin assembly is independent of MEK1   
inhibition [14], while inhibition of the p38-MAPK pathway by LT blocks the Hsp27 phosphorylation 
cycle, impairing actin assembly and chemotaxis [13]. 
Taken together, these opposite results suggest that p38 MAPK signaling and other pathways like 
Cdc42 or actin regulators, such as MLC or ROCK, may mediate LT effects on actin dynamics. Yet, the 
mechanism by which LT leads to this reorganization of the actin cytoskeleton remains unclear. 
4.1.2. Microtubule Network 
While LT induces stress fiber formation in lung epithelial cells, it stabilizes microtubules, with 
multiple, highly active protrusions without formation of a leading edge and MTOC polarization [11]. 
However, proteome and DNA array analysis of mouse macrophages treated with LT induce a notable 
decrease of cellular tubulin [59,62], while LF alone does not appear to directly cleave tubulin [62]. 
DNA array analysis also indicates that microtubule-associating proteins expression (i.e., kinesin Toxins 2012, 4                 
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motor-protein) is altered in LT-treated macrophages [62], suggesting an altered stability of the 
microtubule network in macrophages. 
4.2. ET Effects  
ET induces significant morphological and cytoskeletal changes in different mammalian cells [63], 
including macrophages [10,64,65], primary human microvascular endothelial cells (HMVEC) [12] and 
neutrophils [57] (Figure 2). Some morphological differences have been observed between cells after 
ET treatment: (i) formation of filopodial protrusions in mammalian cells [63,64] versus reduction in 
macrophage [10]; (ii) rounded morphology in macrophages and mammalian cells [10,63,64] versus 
flattened morphology in human microvascular endothelial cells (HMVEC) [12]. In any case, every cell 
type had reduced spread morphology, a lowered F-actin content and actin redistribution to the cell 
margin in a time-dependent manner [10,57,63,64]. 
Some results support a role for the cAMP-dependent Protein Kinase A (PKA) pathway in the 
reorganization of actin network [10,57,63,64]. PKA is a serine-threonine kinase that phosphorylates 
many cytoskeletal proteins, including actin, microtubules and intermediate filaments. The role of 
Exchange Protein Activated by cAMP (Epac) is less clear, as one study on mammalian cells suggest a 
lack of Epac activation [63], while another suggests an activation of Epac and Ras-proximate-1 (Rap1) 
pathway alone [12], or associated with PKA signaling [10]. The disruption in the balance of Epac/PKA 
activity seems to be responsible for these cytoskeleton’s effects. As for LT effects, it clearly appears 
that ET-related cytoskeleton disruption and intracellular signaling are cell type-dependent. So far, no 
studies have explored the potential effect of ET on microtubules. 
Because of its biochemical adenylate cyclase activity, ET may be compared to toxins with   
identical  functions: ExoY of Pseudomonas aeruginosa [66] or adenylate cyclase toxin of   
Bordetella pertussis [67].  B. pertussis, the causative agent of whooping cough, produces toxins 
including an adenylate cyclase (CyaA) which also possesses hemolytic activity. It appears clearly that 
CyaA causes morphological changes [68–70], including membrane blebbing in erythrocytes [70]. 
Recent work by Kamanova et al. demonstrated that the adenylate cyclase activity of CyaA causes 
transient and selective inactivation of the GTPase RhoA in mouse macrophages and activation   
of cofilin, leading to massive actin rearrangements. These latter effects wane faster at high   
toxin concentration and are accompanied by a formation of membrane extensions referred as   
lamellipodia or membrane ruffling [71]. Consequently, cAMP signaling of CyaA toxin rapidly halts  
complement-mediated phagocytosis of macrophages [71] and human neutrophils [69,72,73].  
Soluble adenylate cyclase ExoY of P. aeruginosa, injected by a type III secretion system in a host 
also generates a cAMP pool in the cytosol and mimicked using a forskolin activated soluble adenylyl 
cyclase I/II (sACI/II) by several authors ([74] and reviewed in [75]). Activation of sACI/II or directly 
ExoY generates a large cAMP increase that induces endothelial cell retraction [74,75], with an intact 
cortical F-actin network and a decrease of MLC phosphorylation [74] and probably a role in bleb-niche 
formation in epithelial cells [76]. 
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5. From the Cytoskeleton up to Cellular and Organ Disruption 
Anthrax toxins have many effects on the cytoskeleton. We will examine here the consequences of 
cytoskeleton disruption on some key cell functions and at the organ level. We focus our analysis here 
on two paradigms of cell function and organ disruption: cell phagocytosis and vascular integrity. 
5.1. B. anthracis Toxins, Cytoskeleton and Phagocytosis Disruption  
Phagocytosis is one of the first innate defense mechanisms involved for pathogen scavenging. 
Moreover, phagocytosis activates the adaptive immune system by antigen presentation. As B. anthracis 
escapes so efficiently from the innate and adaptive immune response, phagocytosis disruption by 
anthrax toxins does not come as a surprise. 
In vivo, LT inhibits primary peritoneal macrophages fluorescent microspheres phagocytosis after 
LT-intraperitoneal injection [77], even though cultured nonhuman primate alveolar macrophages are 
still capable of spore phagocytosis after LT treatment [78]. Recently, Kau et al. demonstrate that LT 
suppresses the phagocytosis of J774 macrophage cells at low doses without influencing the MAPK 
pathways during early infection [79], implicating another pathway. Nevertheless, these effects are 
unclear and do not affirm that phagocytosis is inhibited by LT. 
The effect of ET on human neutrophils [80] or human macrophages [10] shows a reduction, even an 
inhibition, of the phagocytic capacity of these cells. This is largely due to an inability to undergo actin 
remodeling, required for phagocytic activities. However, it clearly appears that aspects of ET-related 
actin cytoskeleton on phagocytic capacities of B. anthracis Ames spores depend on the cell type [10]. 
The cytoskeleton disruption by anthrax toxins and potential consequences on phagocytosis is likely 
important during later stages of infection and would benefit pathogen survival. The ability of these 
toxins to reduce or inhibit phagocyte functions represents a dangerous immuno-evasive mechanism 
where the extracellular vegetative cells can rapidly multiply and be eliminated with difficulty. 
5.2. Anthrax Toxins and Vascular Disruption 
Corruption of vascular integrity by ET has been known since its discovery in the mid 1960s, as it 
was named after its effects observed following subcutaneous injection [81]. These observations could 
be related to clinical records in oro-pharyngeal anthrax, an uncommon form of the disease characterized 
by impressive neck swelling [82]. Interestingly, subcutaneous versus intravascular injection of ET are 
not symmetrical, as they do not lead to the same outcome. On one hand a local reversible edema is 
only observed, while on the other hand the toxin is lethal [83]. This observation has one corollary: 
toxins act differentially when in the blood lumen or out of the vessel. When both anthrax toxins enter 
the bloodstream, they corrupt vascular homeostasis leading to a cardio-vascular collapse (review   
in [8,84]). From a pathogen’s standpoint both toxins facilitate pathogen spread, as they breach the 
vascular barrier between the blood and tissues leading to bacilli proliferation in multiple organs 
(review in [84]). These results suggest that ET may have been selected throughout evolution for its 
effects at the last stage of the disease when it is released into the bloodstream. Recent studies have 
confirmed that LT opens the blood-brain barrier favoring meningitis, one of the most frequent 
complications of systemic anthrax [85,86]. Toxins 2012, 4                 
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Surprisingly, anthrax toxins target the vascular endothelial system but are still poorly described 
mechanistically (let alone the cardiac effects). LT disrupts in vitro vascular endothelial cells by 
increasing actin stress fibers and disorganizing VE-cadherin at the adherents junctions (AJ) gasket [87] 
and protein zona occludens-1 at tight junctions (TJ) [85]. In vivo LT increases vascular permeability  
in zebrafish [88]. ET has also significant disrupting effects on cadherin in AJ [89]. Strikingly, 
mechanistic insights have been brought by a group using Drosophila as a model to deconstruct   
host-pathogen interactions [90,91]. They have very elegantly shown that ET and LT vascular effects 
are caused through a coordinate disruption of Rab11/sec15 exocyst [89]. The exocyst complex regulates 
docking of specific cargo vesicles to AJ. By deregulating AJ, both toxins corrupt cytoskeleton 
organization and vascular permeability. Another effect of toxin on vascular permeability is the 
formation of transendothelial macro-aperture (TEM) [92]. Very recently ET has been shown to induce 
TEMs, thus increasing peripheral vascular permeability [93]. More interestingly, the cytoskeleton 
senses the formation of TEM through a protein called Missing in Metastasis (MIM) that senses 
de novo membrane curvature, ultimately driving Arp2/3-dependent actin polymerization [93]. These 
very well designed studies clearly demonstrate the role of cytoskeleton in maintaining vascular 
integrity that is challenged by ET. 
6. Conclusions-Perspectives 
As we have shown here, the cytoskeleton emerges as the central target of anthrax toxin effects. As 
the cytoskeleton plays a crucial role in eukaryote cell biology, it is not surprising that toxins act on the 
central coordinator of cell life. New tools are emerging as the cytoskeleton is studied for its central role 
in cancer and development biology. Moreover, whereas ET and LT synergize their action against host 
innate immunity [94], the simultaneous effects of these two toxins on the cytoskeleton have only been 
examined by Szarowicz et al. [57]. This latter study suggests that the combination of ET and LT 
results in additive reduction in F-actin content, suggesting that these toxins impair actin assembly by 
different signaling pathways. So, it appears necessary to better understand the simultaneous effects of 
the two toxins on the cytoskeleton and the functional consequences for phagocytes. Thus, these 
elements would address the issue of whether ET and LT act in synergy or opposition to the 
cytoskeleton of phagocytes. A better understanding of B. anthracis toxin effects may allow the 
discovery of new inhibitors and better ways to treat anthrax. Outlined here are new avenues for 
researchers covering central questions that remain to be answered, such as the description of toxin 
effects as well as their potential synergistic effects upon the actin cytoskeleton. 
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